UPDATE 1-U.S. FDA approves Otsuka and Lundbeck's schizophrenia treatment
July 10, 2015 at 20:59 PM EDT
July 10 (Reuters) - The U.S. Food and Drug Administration approved Danish drugmaker H. Lundbeck A/S and Japan's Otsuka Pharmaceutical Co Ltd's Rexulti, an anti-psychotic drug used to treat schizophrenia.